AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen RSS Channel

Display # 
Title Published Date
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US 28 October 2015
Amgen to acquire privately-held Dezima Pharma 16 September 2015
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation 16 September 2015
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab) 23 July 2015
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab 02 June 2015
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia 01 July 2014
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma 05 February 2014
Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry 07 November 2013
Amgen's third quarter 2013 revenues increased 10 percent 24 October 2013
Amgen acquires Filgrastim franchise rights from Roche In 100 markets 22 October 2013
Amgen successfully completes Onyx Pharmaceuticals tender offer 02 October 2013
Amgen and ShanghaiTech University announce plans for Amgen China R&D center 25 September 2013
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash 26 August 2013
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone 16 June 2013
Amgen and Astellas announce Japan Alliance 29 May 2013
Amgen and Zhejiang Beta Pharma announce planned joint venture in China 10 May 2013
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma 20 March 2013
Amgen's full year 2012 revenues increased 11 percent to $17.3 billion 23 January 2013
Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion 26 July 2012
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response 17 May 2012

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]